Subscribe
Sign in
Subscribe
Sign in
GlobalData
GlobalData

Pharma

GlobalData Healthcare to host webinar on China’s next frontier in biopharma dealmaking

China’s biopharma sector is moving from a sourcing option to a strategic priority for global pharma, with deal structures shifting from single-asset licensing to full platform acquisitions. To help healthcare and life sciences leaders navigate this shift, GlobalData Healthcare, the pharmaceutical and life sciences intelligence arm of GlobalData, a leading intelligence and productivity platform, will […]
Read more

China expands role in manufacturing new FDA-approved drugs, says GlobalData

Biopharma companies are increasingly choosing to manufacture their newer FDA-approved innovator and biosimilar products at facilities in China, signaling growing industry confidence in using the country as one of the bases for its manufacturing, according to GlobalData, a leading intelligence and productivity platform. Katia Djebbar, Pharma Analyst at GlobalData, comments: “The FDA-approved products currently being […]
Read more

South Korea’s dry eye market to see intensified competition with third homegrown drug approval, says GlobalData

South Korea’s Ministry of Food and Drug Safety has approved recoflavone (Latica/Recodu) for moderate to severe dry eye disease. Developed jointly by GL PharmaTech and Aju Pharmaceutical, recoflavone is the first domestically developed dry eye disease treatment approved in South Korea and the third prescription treatment authorized for the indication. The approval is expected to […]
Read more

CDMOs invest in European API capabilities to balance changing demand and supply chain risks, says GlobalData

Contract development and manufacturing organizations (CDMOs) are ramping up their active pharmaceutical ingredient (API) investments in Europe. A series of recent deals shows how companies are strengthening their infrastructure in the region, as they position themselves to develop and supply newer, more complex medicines, says GlobalData, a leading intelligence and productivity platform. GlobalData’s monthly Bio/Pharmaceutical […]
Read more

Classical Hodgkin lymphoma diagnosed incident cases to reach 28,000 across 8MM in 2035, forecasts GlobalData

The burden of diagnosed incident cases of classical Hodgkin lymphoma in the 8MM* is forecast to increase at an annual growth rate (AGR) of 0.31%, from 27,000 in 2025 to 28,000 cases in 2035, according to GlobalData, a leading intelligence and productivity platform. GlobalData’s latest report, “Hodgkin Lymphoma: Epidemiology Report and Forecast,” reveals that the […]
Read more

Lunsekimig results bolster Sanofi’s strategy to defend respiratory franchise ahead of Dupixent patent expiry, says GlobalData

Lunsekimig’s Phase IIb asthma data strengthen its case as a differentiated next-generation biologic, with dose-dependent reductions in exacerbations and improvements in lung function supporting progression into Phase III. The results could sharpen Sanofi’s strategy to defend its respiratory franchise ahead of Dupixent’s patent expiry, while intensifying competition in an increasingly crowded asthma biologics market, says […]
Read more

Tozorakimab results broaden biologic treatment across COPD population, says GlobalData

Tozorakimab’s (interleukin-33 (IL-33) inhibitor) Phase III chronic obstructive pulmonary disease (COPD) results strengthen the case for a new class of biologic treatment that could extend beyond eosinophil-defined patients. Consistent efficacy across OBERON and TITANIA trials, including those with low eosinophil counts, could broaden the addressable COPD population and intensify competition in a market where current […]
Read more

Mabwell’s 9MW1911 data support further testing of ST2 blockade in COPD, says GlobalData

At the European Respiratory Society (ERS) Congress 2026, Mabwell and collaborating investigators presented results from the company’s Phase Ib/IIa study in patients with chronic obstructive pulmonary disease (COPD). The randomized, double-blind, placebo-controlled trial evaluated the therapeutic efficacy and safety of 9MW1911, an anti-ST2 monoclonal antibody, in moderate-to-severe COPD. Although the efficacy findings were exploratory and […]
Read more

China’s rise as a biopharma innovation hub reshapes global dealmaking strategies, says GlobalData

China’s biopharma ecosystem is reshaping how global pharmaceutical companies source innovation, build pipelines and structure deals. As Chinese-origin assets gain global validation and licensing values rise, China is becoming an increasingly strategic component of international growth strategies while regulatory and geopolitical complexity raises the stakes for companies deciding how deeply to engage, says GlobalData Healthcare, […]
Read more

ERS 2026 data positions Infex’s RESP-X at forefront of Pa-colonized NCFB space, says GlobalData

At the 2026 European Respiratory Society (ERS) International Congress, Infex Therapeutics presented a new analysis of Phase IIa results for RESP-X (INFEX702) in P. aeruginosa (Pa)-colonized non-cystic fibrosis bronchiectasis (NCFB). This matters because, despite the 2025 approval of Insmed’s Brinsupri (brensocatib) as the first therapy for NCFB, no approved treatment yet targets Pa, the disease’s […]
Read more

BI 1839100’s termination raises questions for TRPA-1 targeting in IPF cough, says GlobalData

At the 2026 European Respiratory Society (ERS) International Congress, Boehringer Ingelheim (BI) presented results from the Phase IIa/IIb trial of BI 1839100, an investigational asset for chronic cough in idiopathic pulmonary fibrosis (IPF). BI terminated the trial in 2025, citing a sponsor decision ahead of planned completion, and also terminated a separate Phase I mass-balance/ADME […]
Read more

Jascayd mortality data strengthens case for earlier treatment of IPF and PPF, says GlobalData

New mortality data for Jascayd (nerandomilast) strengthens the case for earlier treatment of idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF), showing meaningful survival benefits among patients with preserved lung function. The findings could reshape payer and prescribing decisions, supporting broader first-line use in Europe while giving Boehringer Ingelheim (BI) a stronger commercial narrative […]
Read more

MRSA therapeutics market to reach $1.8 billion across 7MM in 2034, forecasts GlobalData

The methicillin-resistant Staphylococcus aureus(MRSA) therapeutics market across the seven major pharmaceutical markets (7MM*) is forecast to grow at a compound annual growth rate (CAGR) of 3.4%, from $1.3 billion in 2024 to $1.8 billion in 2034, according to GlobalData, a leading intelligence and productivity platform. GlobalData’s report, “Methicillin-Resistant Staphylococcus aureus Therapeutics: Seven-Market Drug Forecast”, reveals […]
Read more

Foreign CMOs expand US capacity as pharma supply chains regionalize, reveals GlobalData

Foreign contract manufacturing organizations (CMOs) are accelerating investment in US manufacturing as pharmaceutical companies prioritize supply-chain resilience, regional capacity and greater control over production. The recent site upgrades, acquisitions and new partnerships signal a shift from cost-driven outsourcing toward integrated, locally anchored models, giving sponsors broader access to end-to-end capabilities while reducing exposure to geopolitical, […]
Read more

Daraxonrasib approval changes standard of care in second-line pancreatic cancer, says GlobalData

The US FDA approval of Revolution Medicine’s Rasonque (daraxonrasib) changes the standard of care in second-line pancreatic cancer, as the oral therapy will displace the intensive and complicated-to-administer chemotherapy regimens currently used in practice, revealsGlobalData, a leading intelligence and productivity platform. Israel Stern, Healthcare Senior Analyst at GlobalData, comments. “Unlike first-generation RAS inhibitors, that only bind […]
Read more

Biogen’s felzartamab approval to intensify competition in crowded multiple myeloma market in China, says GlobalData

China has recently approved TJ Biopharma’s felzartamab (Jingfei) as the third CD38 inhibitor for multiple myeloma, marking the first approved indication for the drug. This approval marks entry of Biogen into the oncology commercial space in China and intensifies competition in an already crowded multiple myeloma market, according to GlobalData, a leading intelligence and productivity […]
Read more
1 2 3 … 110